97 related articles for article (PubMed ID: 19889051)
1. Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization.
Porto DA; Comfere NI; Myers LM; Abbott JJ
J Cutan Pathol; 2010 Oct; 37(10):1098-102. PubMed ID: 19889051
[TBL] [Abstract][Full Text] [Related]
2. [Reactivation of herpes zoster infection by varicella-zoster virus].
Cvjetković D; Jovanović J; Hrnjaković-Cvjetković I; Brkić S; Bogdanović M
Med Pregl; 1999; 52(3-5):125-8. PubMed ID: 10518396
[TBL] [Abstract][Full Text] [Related]
3. Zoster vaccine: current status and future prospects.
Oxman MN
Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
[TBL] [Abstract][Full Text] [Related]
4. Herpes zoster virus vaccine.
Woolery WA
Geriatrics; 2008 Oct; 63(10):6-9. PubMed ID: 18828650
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
6. Detection of varicella zoster virus DNA and viral antigen in human eyes after herpes zoster ophthalmicus.
Wenkel H; Rummelt V; Fleckenstein B; Naumann GO
Ophthalmology; 1998 Jul; 105(7):1323-30. PubMed ID: 9663241
[TBL] [Abstract][Full Text] [Related]
7. Hyperplasia of hair follicles and other adnexal structures in cutaneous lymphoproliferative disorders: a study of 53 cases, including so-called pseudolymphomatous folliculitis and overt lymphomas.
Kazakov DV; Belousova IE; Kacerovska D; Sima R; Vanecek T; Vazmitel M; Pizinger K; Michal M
Am J Surg Pathol; 2008 Oct; 32(10):1468-78. PubMed ID: 18685486
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
Lu PJ; Euler GL; Jumaan AO; Harpaz R
Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
[TBL] [Abstract][Full Text] [Related]
9. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of varicella zoster virus (VZV) copy DNA numbers in plasma of immunocompetent patients with herpes zoster, of immunocompromised patients with disseminated VZV disease, and of asymptomatic solid organ transplant recipients.
Kronenberg A; Bossart W; Wuthrich RP; Cao C; Lautenschlager S; Wiegand ND; Mullhaupt B; Noll G; Mueller NJ; Speck RF
Transpl Infect Dis; 2005; 7(3-4):116-21. PubMed ID: 16390399
[TBL] [Abstract][Full Text] [Related]
11. Prevention of shingles by varicella zoster virus vaccination.
Holodniy M
Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624
[TBL] [Abstract][Full Text] [Related]
12. Latency and reactivation of varicella zoster virus infections.
Dueland AN
Scand J Infect Dis Suppl; 1996; 100():46-50. PubMed ID: 9163025
[TBL] [Abstract][Full Text] [Related]
13. Why should older adults receive the shingles vaccine?
Harkness TL
J Gerontol Nurs; 2010 Oct; 36(10):51-5. PubMed ID: 20506935
[TBL] [Abstract][Full Text] [Related]
14. Varicella-zoster-virus folliculitis promoted clonal cutaneous lymphoid hyperplasia.
Aram G; Rohwedder A; Nazeer T; Shoss R; Fisher A; Carlson JA
Am J Dermatopathol; 2005 Oct; 27(5):411-7. PubMed ID: 16148411
[TBL] [Abstract][Full Text] [Related]
15. Rapid molecular discrimination between infection with wild-type varicella-zoster virus and varicella vaccine virus.
Lässker U; Harder TC; Hufnagel M; Suttorp M
Infection; 2002 Oct; 30(5):320-2. PubMed ID: 12382096
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
[TBL] [Abstract][Full Text] [Related]
17. Molecular and therapeutic aspects of varicella-zoster virus infection.
Quinlivan M; Breuer J
Expert Rev Mol Med; 2005 Aug; 7(15):1-24. PubMed ID: 16098235
[TBL] [Abstract][Full Text] [Related]
18. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
Tyring SK; Diaz-Mitoma F; Padget LG; Nunez M; Poland G; Cassidy WM; Bundick ND; Li J; Chan IS; Stek JE; Annunziato PW;
Vaccine; 2007 Feb; 25(10):1877-83. PubMed ID: 17227688
[TBL] [Abstract][Full Text] [Related]
20. Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old.
Ota K; Kim V; Lavi S; Ford-Jones EL; Tipples G; Scolnik D; Tellier R
Pediatr Infect Dis J; 2008 Sep; 27(9):847-8. PubMed ID: 18664930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
